Profile of:

Walter Maksymowych

Walter P. Maksymowych, MB ChB, FRCP(C), FACP, is a Professor, Clinician, and Medical Scientist in the Department of Medicine, Division of Rheumatology at the University of Alberta, Edmonton, Canada. He is Canadian Royal College and American Board of Internal Medicine certified in Internal Medicine and Rheumatology. He is the 2012 recipient of the Distinguished Investigator Award from the Canadian Rheumatology Association. He founded CARE Arthritis Limited, a Canadian company focused on the development of personalized medicine strategies for patients with arthritis, and now serves as Chief Medical Officer. Dr. Maksymowych graduated from the University of Manchester School of Medicine, United Kingdom, in 1981 and completed his postgraduate training at the Universities of Alberta, Canada, and Cincinnati, USA. His primary research interests are the imaging and treatment of spondyloarthritis, and the clinical validation of biomarker technologies for rheumatic diseases. He has published over 400 research articles and is an active member of numerous international societies related to arthritis. He is co-developer of the SPARCC MRI scoring systems for inflammation and structural damage in the sacroiliac joints and spine that are now industry standard in clinical trials. Most recently, he co-invented the 14-3-3 biomarker which is now licensed for diagnostic testing of patients with rheumatoid arthritis.

Full name: Walter Maksymowych

Current country: Canada

Membership level: Full

Type of membership: Member

Number of publications: 24

Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. (2021)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. (2021)

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. (2021)

A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. (2021)

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. (2021)

Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). (2021)

Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. (2021)

Utility of magnetic resonance imaging in Crohn’s associated sacroiliitis: A cross-sectional study (2021)

Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis. (2021)

The ASAS-OMERACT core domain set for axial spondyloarthritis. (2021)

Imaging in Axial Spondyloarthritis: What is Relevant for Diagnosis in Daily Practice? (2021)

Joint and entheseal inflammation in the knee region in spondyloarthritis – reliability and responsiveness of two OMERACT whole-body MRI scores. (2021)

Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis – OMERACT validation of two whole-body MRI methods. (2021)

Atlas of MRI findings of sacroiliitis in pediatric sacroiliac joints to accompany the updated preliminary OMERACT pediatric JAMRIS (Juvenile Idiopathic Arthritis MRI Score) scoring system: Part II: Structural damage lesions. (2021)

Atlas of MRI findings of sacroiliitis in pediatric sacroiliac joints to accompany the updated preliminary OMERACT pediatric JAMRIS (Juvenile Idiopathic Arthritis MRI Score) scoring system: Part I: Active lesions. (2021)

JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials. (2021)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis from the Alberta Prospective Cohort. (2021)

Long-term Tolerability and Efficacy of Golimumab in Active Non-Radiographic Axial Spondyloarthritis: Results from Open-Label Extension. (2021)

Radiographic sacroiliitis progression in axial spondyloarthritis: Central reading of 5 year follow-up data from the Assessment of Spondyloarthritis international Society cohort. (2021)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. (2021)

Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: A 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. (2021)

Data-Driven Definitions for Active and Structural MRI Lesions in the Sacroiliac Joint in Spondyloarthritis and their Predictive Utility. (2021)

The paradigm of non-radiographic sacroiliitis – why the ongoing doubts? (2021)

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. (2021)